The VICT3R Community brings together a diverse group of actors – from project partners and collaborating organizations to regulatory and policymaking experts.
Together, we are working to develop and implement Virtual Control Groups (VCGs) as a way to transform nonclinical safety evaluations, reduce reliance on animal testing, and promote ethical research practices. By combining cutting-edge technologies with broad expertise, this joint effort is paving the way for new standards in drug and chemical safety assessment.
VICT3R Beneficiaries
The VICT3R consortium, led by Pompeu Fabra University (Spain) and Bayer Aktiengesellschaft (Germany) brings together 37 partner organisations in a dynamic public–private partnership. This diverse alliance includes 23 industry leaders, eight innovative small and medium-sized enterprises, and six renowned academic institutions.
Abbvie Inc
North Chicago, Illinois, United States
Amgen Research (Munich) GmbH
München, Germany
Astrazeneca Uk Limited
Cambridge, United Kingdom
Barcelona Supercomputing Center – Centro Nacional de Supercomputación
Barcelona, Spain
BASF SE
Ludwigshafen am Rhein, Germany
Bayer Aktiengesellschaft
Leverkusen, Germany
Boehringer Ingelheim International GmbH
Ingelheim, Germany
Bristol-Myers Squibb Company Corp
Princeton, NJ, United States
CAATevents gGmbH
Solingen, Germany
Deciphex
Dublin, Ireland
F. Hoffmann-La Roche AG
Basel, Switzerland
Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM)
Hanover, Germany
GlaxoSmithKline Research & Development Limited
London, United Kingdom
grit42
Copenhagen, Denmark
Incyte Biosciences Distribution B.V
Amsterdam, Netherlands
Instem
Stone Staffordshire, United Kingdom
Ipsen Innovation SAS
Les Ulis, France
Janssen Pharmaceutica Nv
Beerse, Belgium
Medbioinformatics Solutions SL
Barcelona, Spain
Merck Kommanditgesellschaft Auf Aktien
Darmstadt, Germany
Novartis Pharma AG
Basel, Switzerland
Novo Nordisk A/S
Bagsvaerd, Denmark
Organon SRL
București, Romania
Orion Corporation
Espoo, Finland
Pfizer Inc
New York City, United States
PHUSE CLG
Dublin, Ireland
Sanofi-Aventis Deutschland GmbH
Frankfurt / Main, Germany
Servier – R&D Institute Paris-Saclay
Gif-sur-Yvette, France
Synapse Research Management Partners SL
Barcelona, Spain
Syncwork Aktiengesellschaft
Berlin, Germany
Takeda Pharmaceuticals International AG
Glattpark-Opfikon, Zurich, Switzerland
TU Dortmund University
Dortmund, Germany
UCB Biopharma
Brussels, Belgium
Universitat Pompeu Fabra
Barcelona, Spain
University of Konstanz
Konstanz, Germany
Vrije Universiteit Brussel
Brussel, Belgium
Zoetis Belgium SA
Louvain La Neuve, Belgium
VICT3R beneficiaries
The VICT3R consortium, led by Pompeu Fabra University (Spain) and Bayer Aktiengesellschaft (Germany) brings together 37 partner organisations in a dynamic public–private partnership. This diverse alliance includes 23 industry leaders, eight innovative small and medium-sized enterprises, and six renowned academic institutions.
Universities, research organisations, public bodies, non-profit groups
Barcelona Supercomputing Center – Centro Nacional de Supercomputación
Barcelona, Spain
Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM)
Hanover, Germany
TU Dortmund University
Dortmund, Germany
Universitat Pompeu Fabra
Barcelona, Spain
University of Konstanz
Konstanz, Germany
Vrije Universiteit Brussel
Brussel, Belgium
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
IHI industry partners
Abbvie Inc
North Chicago, Illinois, United States
Amgen Research (Munich) GmbH
München, Germany
Astrazeneca Uk Limited
Cambridge, United Kingdom
BASF SE
Ludwigshafen am Rhein, Germany
Bayer Aktiengesellschaft
Leverkusen, Germany
Boehringer Ingelheim International GmbH
Ingelheim, Germany
Bristol-Myers Squibb Company Corp
Princeton, NJ, United States
F. Hoffmann-La Roche AG
Basel, Switzerland
GlaxoSmithKline Research & Development Limited
London, United Kingdom
Incyte Biosciences Distribution B.V
Amsterdam, Netherlands
Ipsen Innovation SAS
Les Ulis, France
Janssen Pharmaceutica Nv
Beerse, Belgium
Merck Kommanditgesellschaft Auf Aktien
Darmstadt, Germany
Novartis Pharma AG
Basel, Switzerland
Novo Nordisk A/S
Bagsvaerd, Denmark
Orion Corporation
Espoo, Finland
Pfizer Inc
New York City, United States
Sanofi-Aventis Deutschland GmbH
Frankfurt / Main, Germany
Servier – R&D Institute Paris-Saclay
Gif-sur-Yvette, France
Takeda Pharmaceuticals International AG
Glattpark-Opfikon, Zurich, Switzerland
UCB Biopharma
Brussels, Belgium
Zoetis Belgium SA
Louvain La Neuve, Belgium
Barcelona Supercomputing Center - Centro Nacional de Supercomputación
Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM)
TU Dortmund University
Universitat Pompeu Fabra
University of Konstanz
Vrije Universiteit Brussel
Deciphex
grit42
Medbioinformatics Solutions SL
Organon SRL, București, Romania
PHUSE CLG
Synapse Research Management Partners SL
Syncwork Aktiengesellschaft, Berlin, Germany
Abbvie Inc
Amgen Research (Munich) GmbH
Astrazeneca Uk Limited
BASF SE
Bayer Aktiengesellschaft
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Company Corp
F. Hoffmann-La Roche AG, Basel, Switzerland
Incyte Biosciences Distribution B.V, Amsterdam, Netherlands
Ipsen Innovation SAS
Janssen Pharmaceutica Nv
Merck Kommanditgesellschaft Auf Aktien
Novartis Pharma AG
Novo Nordisk A/S
Orion Corporation, Espoo, Finland
Pfizer Inc
Sanofi-Aventis Deutschland GmbH
Takeda Pharmaceuticals International AG
UCB Biopharma
Instem, Stone Staffordshire
Collaborating Organisations
Other organisations have formally joined the VICT3R Community through the signing of Associated CRO Agreements. These organisations contribute valuable study data and decades of experience to support the development of Virtual Control Groups (VCGs) − a cornerstone of VICT3R.
Advisors
VICT3R is supported by a Scientific and Regulatory Advisory Board (SRAB), which provides independent external advice to the project. The SRAB members bring expertise in key areas relevant to the project, helping to guide its scientific and regulatory strategy. The members are:
Susanne Brendler-Schwaab
BfArM (Federal Institute for Drugs and Medical Devices, Germany)
Philip Marx-Stoelting
BfR (Federal Institute for Risk Assessment, Germany)
Ilona Kareinen
ECHA (European Chemicals Agency)
Roman Liska
ECVAM, JRC (European Centre for the Validation of Alternative Methods, European Commissions Joint Research Centre)
Alison Harrill
EPA (US Environmental Protection Agency)
Suzanne C. Fitzpatrick
FDA (US Food and Drug Administration)
Peter van Meer
MEB (Medicines Evaluation Board, The Netherlands)
Patience Browne
OECD (Organisation for Economic Co-operation and Development)
Vera Rogiers
Toxicology Expert – independent
François Pognan
Toxicology Expert – independent
